Related Experiment Videos
[Ankylosing spondylitis is associated with increased cardiovascular morbidity and mortality]
Ole Rintek Madsen1, Jesper Lindhardsen
1Reumatologisk Funktion, Medicinsk Afdeling C, Gentofte Hospital, 2900 Hellerup, Denmark. rintek@dadlnet.dk
Insights
Ankylosing spondylitis patients face higher cardiovascular risks due to inflammation and potential treatment side effects. Managing traditional risk factors is crucial for better heart health outcomes in these individuals.
Area of Science:
- Rheumatology
- Cardiology
Context:
- Ankylosing spondylitis (AS) is a chronic inflammatory disease impacting the axial skeleton.
- AS is linked to elevated cardiovascular morbidity and mortality.
- Inflammation-driven cardiac structural changes and atherosclerosis are potential concerns.
Purpose:
- To explore the cardiovascular risk profile in patients with ankylosing spondylitis.
- To investigate the influence of traditional cardiovascular risk factors and anti-inflammatory therapies on cardiovascular outcomes in AS.
- To assess the impact of tumor necrosis factor inhibitors on lipid profiles.
Summary:
- Ankylosing spondylitis patients exhibit increased cardiovascular risk.
- The precise roles of conventional risk factors and anti-inflammatory treatments require further elucidation.
- Tumor necrosis factor inhibitors may elevate cholesterol levels, necessitating careful monitoring.
Impact:
- Highlights the need for comprehensive cardiovascular risk assessment in AS patients.
- Emphasizes the importance of managing cardiovascular risk factors according to established guidelines.
- Suggests a potential link between specific AS treatments and adverse lipid changes.
Abstract:
Ankylosing spondylitis is an inflammatory disorder primarily affecting the axial skeleton. The disease is associated with increased cardiovascular morbidity and mortality. Structural changes in the heart, and arteriosclerosis secondary to inflammation may be of importance. The role of traditional cardiovascular risk factors and of anti-inflammatory treatment is unclear. Tumor necrosis factor inhibitors seem to increase cholesterol levels. Evaluation of the cardiovascular risk in these patients should be considered. Cardiovascular risk factors should be managed according to ordinary guidelines.
Related Concept Videos
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease I: Introduction
Coronary Artery Disease I: Introduction
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations